Organization · Private Equity
Terra Magnum Capital Partners
Terra Magnum Capital Partners is a Beijing-based investment firm founded in 2016, specializing in direct and fund investments in the biopharmaceutical sector. The firm focuses on leveraging its market knowledge and network to support portfolio companies in achieving growth and successful exits.
Overview
What Terra Magnum Capital Partners does
What Terra Magnum Capital Partners is
Terra Magnum Capital Partners is a Beijing-based investment firm founded in 2016, specializing in direct and fund investments in the biopharmaceutical sector. The firm focuses on leveraging its market knowledge and network to support portfolio companies in achieving growth and successful exits.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Private Equity
- Founded
- Founded in 2016
- Approximate age
- About 10 years
- Structured capabilities
- Funder
- Last reviewed
- April 26, 2026
Official channels
Find Terra Magnum Capital Partners elsewhere
Open the official website or a supported primary organization account.
Capability profile
Terra Magnum Capital Partners as a funder
Investment thesis
Terra Magnum Capital Partners combines expertise in the China private equity market with a focus on cross-border biopharmaceutical investments, aiming to support portfolio companies in achieving growth and successful exits.
Focus narrative
TMCP invests primarily in the biopharmaceutical and healthcare sectors, utilizing its capital market expertise to support the growth of its portfolio companies. The firm is particularly interested in companies with meaningful clinical or platform potential that can benefit from China/U.S. market connectivity.
Value beyond capital
TMCP adds value to its portfolio companies through its extensive market knowledge, proprietary network, and capital market expertise, helping them to grow into market leaders and achieve successful exits.
Terms and economics
- Typical check
- $1,000,000–$50,000,000
Focus and fit
- Stages
- Series A · Series B · Growth Equity
- Regions
- Greater China · United States
Availability
- Currently deploying
- Yes
Portfolio and track record
Portfolio context
Iambic Therapeutics: Involved in a $100M raise in November 2025. ArriVent Biopharma: Participated in a Series B transaction in 2023 with a total raise of $155M. Walking Fish Therapeutics: Engaged in a Series A transaction in 2022 with a total raise of $73M. Maze Therapeutics: Notable portfolio company with significant transactions. Arcellx: Entered the portfolio with a Series C transaction in 2021. RNAimmune: Received a $2.35M investment.
Common questions
What to know about Terra Magnum Capital Partners
Upseed classifies Terra Magnum Capital Partners under the Private Equity organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.